ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42

Reports Q2 revenue $211.4M, consensus $190.11M. “We had another record-setting quarter for our Company, with all-time highs in net revenue, adjusted EBITDA, and adjusted EPS, reflecting very strong momentum across our business units,” said Nikhil Lalwani, President and CEO of ANI. “Our Rare Disease team delivered exceptional sequential and year-over-year quarterly growth with Cortrophin Gel, driving prescription demand and new patient starts to new highs. Our Generics business achieved another strong quarter fueled by new product launches and operational excellence, and our initiatives to improve the performance of our retina franchise yielded positive results.” Lalwani continued, “We have made significant progress in building a high-growth, profitable and sustainable Rare Disease business since the launch of Cortrophin Gel in 2022. We now expect Rare Disease revenues to account for approximately 57% of total company revenues in the second half of 2025. Based on the very strong momentum, we are increasing our 2025 guidance for total net revenues, adjusted EBITDA, and adjusted EPS.”